Microbiology & Pathology in Massachusetts

Beacon Biosignals is an AI-driven neurotechnology company specializing in clinical-grade sleep EEG capture and biomarker analysis for drug development and clinical research. The company develops FDA-cleared headband devices (Dreem 3S) that collect high-fidelity sleep electroencephalography data in home and clinical settings, paired with proprietary AI algorithms trained on 200,000+ hours of EEG recordings. Beacon's end-to-end platform supports translational research, clinical trial optimization, and real-world clinical practice across psychiatric disorders (major depressive disorder, schizophrenia, bipolar disorder), neurological conditions, and primary and secondary sleep disorders. The company provides quantitative sleep endpoints and pharmacodynamic biomarkers to identify dose-dependent drug effects, characterize and stratify patient populations, support label expansion claims, and track disease progression. Services include full-service clinical trial support with Clinical Study Operations and Scientific Services teams managing device setup, software integration, data quality assurance, and regulatory reporting. Beacon's technology enables objective measurement of sleep architecture and brain function, reducing participant and site burden compared to traditional methods. The platform integrates secure data upload, low-latency event monitoring for compliance and treatment response assessment, and analytics for cohort identification. Beacon is backed by significant venture funding (Series B upsized to $97 million+ as of April 2026) and serves pharmaceutical development, clinical research organizations, and academic institutions. Products are restricted to clinical trial, diagnostic, and academic research use and are not available for individual consumer purchase.

Verax Biomedical manufactures the Platelet PGD prime®, an FDA-cleared rapid diagnostic test for bacterial contamination detection in blood platelets. The test enables extended 7-day platelet dating, addressing FDA guidance on bacterial risk mitigation in blood collection establishments. The platform uses immunoassay technology to detect bacterial cell wall antigens, including enhanced Acinetobacter species detection, providing visual result interpretation without complex sample pretreatment. Designed for blood banks and transfusion services, the test reduces blood product outdate, improves platelet availability, and delivers cost savings through extended dating protocols. The company provides online training and supports FDA compliance for blood safety diagnostics.

AB Sciex LLC is a global leader in mass spectrometry and capillary electrophoresis solutions for research, clinical diagnostics, and life sciences applications. The company manufactures a comprehensive portfolio of analytical instruments including triple-quadrupole and QTOF mass spectrometers, HPLC-MS systems, and capillary electrophoresis (CE) instruments. SCIEX serves clinical diagnostic laboratories with FDA-cleared in vitro diagnostic (IVD) medical devices for routine testing; pharmaceutical and biopharmaceutical companies for drug development and biologics characterization; contract research organizations for bioanalysis; environmental and food safety testing facilities; and life science research institutions. Core product lines include the Triple Quad 7500 Plus system, ZenoTOF 7600 QTOF system, Citrine clinical IVD mass spectrometers, ExionLC front-end HPLC systems, and Intabio ZT for charge variant analysis. SCIEX OS is the company's proprietary software platform supporting Windows 11 for data acquisition, processing, and instrument control. The company emphasizes speed, sensitivity, resolution, and ease of adoption across routine and complex analytical workflows. Manufacturing and support operations span multiple global regions, with primary headquarters in Marlborough, MA, and sales/service in Redwood City, CA (Americas) and multiple EMEA locations.

Covaris, LLC is a life sciences instrumentation and consumables company specializing in acoustic focused acoustic (AFA) technology for sample preparation and biomolecule extraction. The company designs and manufactures instruments, kits, reagents, and consumables for DNA/RNA shearing, chromatin preparation, proteomics, cell lysis, and FFPE (formalin-fixed paraffin-embedded) tissue extraction. Their product portfolio supports applications in next-generation sequencing (NGS), genomics, proteomics, and clinical/research workflows. Covaris offers both off-the-shelf instruments and kits as well as custom service capabilities including FFPE extraction services, sample preparation and nucleic acid shearing services, and custom development projects. The truCOLLECT Solution represents their recent entry into decentralized blood collection with integrated DNA extraction for clinical research and biopharma applications. The company serves research laboratories, clinical diagnostics, and biopharma organizations. Covaris maintains comprehensive technical support including protocols, user manuals, software downloads, and participates in major life sciences conferences and events.

Spectrum Fertility Genomics is a leading provider of cutting-edge solutions for In Vitro Fertilization (IVF) and reproductive genomics. The company specializes in epigenomic innovation and genetic analysis tools designed to support fertility clinics, reproductive laboratories, and healthcare professionals. Their product portfolio includes preimplantation genetic diagnostic (PGD) kits and DNA methylation detection assays used in IVF embryo screening and selection. The company positions itself as a trusted partner for assisted reproductive technology (ART) providers, offering molecular diagnostic solutions that help improve fertility outcomes by enabling genomic profiling of embryos prior to implantation. Spectrum Fertility Genomics maintains strategic partnerships with international life science companies and actively participates in professional conferences including the American Society for Reproductive Medicine (ASRM) and the Preimplantation Genetic Diagnosis International Society (PGDIS), indicating alignment with clinical and regulatory standards in the reproductive medicine field.

LGC Clinical Diagnostics is a global manufacturer specializing in quality management tools, reagent components, biological materials, and diagnostic solutions for the in vitro diagnostics (IVD) and life sciences sectors. As a division of the LGC Group, the company integrates expertise from multiple brands including Technopath Clinical Diagnostics, SeraCare, Biochemical Diagnostics, Kova International, Maine Standards, and The Native Antigen Company. The company manufactures comprehensive portfolios of catalog and custom-developed diagnostic quality solutions, serving over 27,500 customers worldwide including IVD manufacturers, clinical laboratories, biopharmaceutical companies, and academic institutions. Products and services include quality controls, reference materials, linearity and calibration verification solutions, antigens and antibodies, drugs of abuse quality controls, urinalysis quality controls, and external quality assessment (EQA) proficiency testing programs. All facilities are FDA-registered and certified to ISO 13485 and ISO 9001 standards, demonstrating commitment to quality and regulatory compliance throughout the diagnostic pipeline from early research to routine clinical use.

Cellay, Inc. manufactures oligonucleotide FISH (fluorescence in situ hybridization) probes for cytogenetic and molecular diagnostic applications. The company specializes in Same Day OligoFISH® Probes—short, chemically synthesized and labeled oligonucleotides designed to enumerate chromosomes with rapid hybridization kinetics (5–10 minutes at room temperature/isothermal processing). Products are manufactured under cGMP standards, supporting clinical laboratory workflows for chromosome analysis and cytogenetic testing. Cellay's probes are marketed as analyte-specific reagents (ASRs) and are covered by pending US and worldwide patent applications. The company serves clinical laboratories and research institutions requiring fast, efficient FISH probe solutions for karyotyping and chromosomal abnormality detection. Note: Same Day OligoFISH® Probes have not received FDA approval or clearance for cancer detection or diagnosis.

Waters Corporation is a global manufacturer of analytical laboratory instruments, consumables, software, and services headquartered in Milford, Massachusetts. The company specializes in chromatography, mass spectrometry, and sample preparation technologies for pharmaceutical, biopharmaceutical, clinical diagnostics, and life science research applications. Waters' product portfolio includes liquid chromatography (LC) and ultra-performance liquid chromatography (UPLC) systems, mass spectrometry instruments, columns, sample preparation and filtration supplies, and laboratory informatics software. Key product lines include the BioAccord System for biotherapeutic analysis, Xevo mass spectrometers for bioanalytical applications, and biphenyl columns with MaxPeak HPS technology for enhanced separation. The company serves biopharma and pharma development, clinical research and diagnostics, food and beverage testing, forensics, environmental analysis, and cannabis testing markets. Waters provides comprehensive services including instrument support, technical training, application development, and the FlexUP Technology Trade-In Program. The company recently combined with BD Biosciences and Diagnostic Solutions, and received FDA clearance for an at-home cervical cancer screening tool. Waters operates a global distribution network and maintains regulatory compliance across major markets. The company offers online shopping, customized quoting, educational resources, and multi-channel customer support.

Vistapath Biosystems is a software-focused medical technology company headquartered in Cambridge, MA. The company develops Sentinel, an end-to-end digital grossing platform designed to modernize pathology laboratory workflows. Sentinel automates and optimizes critical lab processes including tissue specimen grossing, enhancing quality, efficiency, and consistency across commercial laboratories, hospital pathology labs, contract research organizations (CROs), and life sciences companies. The platform leverages artificial intelligence to streamline intraoperative and routine pathology operations. Vistapath collaborates with established diagnostic and pathology partners (PathAI, Gestalt Diagnostics, PathGroup, Freedom Pathology Laboratories) to validate and deploy the Sentinel platform across clinical and research settings. The company targets mid- to large-scale pathology operations seeking digitization and workflow automation. Management includes CEO Tim Spong and VP Sales & Marketing J. Fernando Corredor, who brings over 20 years of medical device industry experience including work with acquired companies (Medtronic, Integra LifeSciences, Samsung) in imaging and AI-driven diagnostics. While regulatory certifications are not explicitly mentioned in available materials, the company's clinical deployment trajectory and partnership with established pathology networks indicate compliance with relevant healthcare software standards.